ESTEVE Acquires HRA Pharma Rare Diseases from Perrigo

Essential Pharma Acquires Renaissance Pharma Ltd

April 2, 2024

Pharmaceuticals

Essential Pharma has completed the acquisition of all issued share capital of Renaissance Pharma Ltd, gaining the clinical-stage immunotherapy Hu14.18K322A (Hu14.18) for treatment of high‑risk neuroblastoma. The deal adds a development‑stage rare disease oncology asset to Essential Pharma's portfolio; Renaissance's CEO Simon Ball and members of the Renaissance team will continue to work with Essential on further development in partnership with St. Jude Children's Research Hospital.

ESTEVE Acquires Regis Technologies

July 31, 2025

Pharmaceuticals

ESTEVE (Esteve Química / ESTEVE CDMO) has acquired Regis Technologies, a Chicago-based contract development and manufacturing organization (CDMO) specializing in small-molecule APIs and separation products. The acquisition gives ESTEVE a physical U.S. presence, expands its early-stage development and cGMP API manufacturing capabilities, and adds ~70 employees to its US team.

Eruptr Acquires Medicom Health's HRA Business

December 14, 2021

Healthcare Services

Eruptr Holdings, Inc. has completed the acquisition of the health risk assessment (HRA) business line of Medicom Health, LLC, expanding Eruptr's digital marketing and patient engagement offerings for hospitals and health systems. The deal adds a market-leading HRA product that is complementary to Eruptr's existing HealthAware solution and supports capability expansion at scale; Eruptr is PE-backed by H.I.G. Growth Partners.

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.

Norgine Acquires Theravia

August 14, 2025

Pharmaceuticals

Norgine has completed the acquisition of Theravia, an international pharmaceutical company focused on therapies for rare and debilitating conditions. Theravia is now a wholly owned subsidiary of Norgine as the buyer begins integration to expand its rare-disease portfolio and extend product reach across Europe and Australia/New Zealand.

Zevra Therapeutics Acquires Acer Therapeutics

November 20, 2023

Pharmaceuticals

Zevra Therapeutics completed the acquisition of Acer Therapeutics in a stock-and-contingent-value-rights transaction, bringing the FDA-approved product OLPRUVA and clinical-stage candidate EDSIVO into Zevra's portfolio and transitioning Zevra to a commercial-stage rare disease company. The deal included Zevra's purchase of Acer's senior secured debt and issuance of approximately 2.96 million shares plus CVRs (up to $76 million), and was followed by a registered direct offering to a healthcare-focused investment fund.